Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nuvectis Pharma, Inc. - Common Stock
(NQ:
NVCT
)
6.280
-0.020 (-0.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
89,743
Open
6.340
Bid (Size)
2.480 (2)
Ask (Size)
7.770 (10)
Prev. Close
6.300
Today's Range
6.050 - 6.590
52wk Range
5.850 - 15.50
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
August 15, 2024
Via
AB Newswire
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
July 18, 2024
Via
AB Newswire
Performance
YTD
-24.25%
-24.25%
1 Month
-3.68%
-3.68%
3 Month
+5.02%
+5.02%
6 Month
-10.67%
-10.67%
1 Year
-57.94%
-57.94%
More News
Read More
Precision Medicine M&A is Transforming the Future of the Biotech Industry
June 17, 2024
Via
AB Newswire
7 Penny Biotech Stocks to Triple Your Investment
May 28, 2024
Via
InvestorPlace
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Recap: Nuvectis Pharma Q3 Earnings
November 08, 2023
Via
Benzinga
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
May 07, 2024
Via
InvestorPlace
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
April 08, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
March 19, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Present at the 36th Annual Roth Conference
March 15, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 14, 2024
Via
Benzinga
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
March 14, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
March 05, 2024
Via
InvestorPlace
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
January 18, 2024
Via
Benzinga
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
December 18, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
October 24, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 17, 2023
Via
Benzinga
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
September 25, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
September 21, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
September 12, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
September 06, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.